Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.
-
Upload
constance-andrews -
Category
Documents
-
view
214 -
download
1
Transcript of Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.
![Page 1: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/1.jpg)
Management of DVT(and a little bit of PE, too)
Jeffrey P Schaefer MSc MD FRCPC
May 24, 2006
![Page 2: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/2.jpg)
Objectives
• Management of Venothrombotic Disease– levels of evidence– epidemiology and diagnostics– initial management of suspected DVT– management of confirmed DVT– special populations– post-thrombotic syndrome
![Page 3: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/3.jpg)
Data Sources - Therapy
American College of Chest Physicians
CHEST Supplement
September 2004
Volume 126(3)
**Uptodate & eMedicine are not recent ***
![Page 4: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/4.jpg)
Grade 1 “Recommend”
IntermediateObservational studiesClear1C
Strong; most patientsRCTs with limitationsClear1B
Strong; most patients, circumstances
No RCTs; strong results extrapolated or strong observational studies
Clear1C+
Strong; applies to most patients and circumstances
RCTs w/o significant limitations
Clear1A
Strength of Recommendation
Methodologic StrengthRisk/
Benefit
Grade
![Page 5: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/5.jpg)
Grade 2 “Suggest”
Very weakObservational studiesUnclear2C
Weak; alternatives likely better for some
RCTs with limitationsUnclear2B
Weak; action depends on circumstances, values
No RCTs; strong results extrapolated or strong observational studies
Unclear2C+
Intermediate; action depends on circumstances, values
RCTs w/o important limitationsUnclear2A
Strength of Recommendation
Methodologic StrengthRisk/
Benefit
Grade
![Page 6: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/6.jpg)
Hierarchy of Evidence: therapy/prevention
• Systematic reviews of RCTs
• A single RCT
• Systematic review of observational
studies
• Physiological studies
• Unsystematic clinical observations
![Page 7: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/7.jpg)
Randomized Clinical TrialPatients with DVT
Treatment A
Outcome among A
Treatment B
random allocation
Outcome among B
![Page 8: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/8.jpg)
Venothrombotic disease (VTED)
• superficial thrombophlebitis
• deep vein thrombosis– lower limb– upper limb
• pulmonary thromboembolism
• post-thrombotic syndrome
![Page 9: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/9.jpg)
Superficial Vein Thrombophlebitis
![Page 10: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/10.jpg)
Potentially Lethal Misnomer SFV = deep
![Page 11: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/11.jpg)
Deep Vein Thrombosis
![Page 12: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/12.jpg)
Calgary Health RegionJan 1 to June 30, 2001
• 1,400 patients investigated for DVT – 33% inpatient– 40% emergency dept– 27% outpatient
• 3,175 patients investigated for PE– 60% inpatient– 25% emergency dept– 15% outpatient QIHI
![Page 13: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/13.jpg)
Calgary Health RegionJan 1 to June 30, 2001
• DVT tests– 4,200 leg ultrasounds
• 2,500 bilateral• 1,700 unilateral
– 95 venograms
• PE tests– 1,400 V/Q scans– 130 CT scans– 100 pulmonary angiograms
• Estimated cost: $1,500,000 QIHI
![Page 14: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/14.jpg)
DVT - diagnosis• Clinical Suspicion - any one feature performs poorly
![Page 15: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/15.jpg)
D - dimer
• D-dimer Assay– D-dimer is breakdown product of fibrinolysis– high sensitivity (98%) & modest specificity (~50%)– useful for excluding DVT and PE– not useful for confirming diagnosis
– SHOULD NOT TO BE USED• post-operative patient• pregnant patient• patient with malignancy
![Page 16: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/16.jpg)
Duplex Ultrasonography
• Duplex US – above knee DVT
• Sens = 96%
• Spec = 96%Haemostasis 23:61-7
• calf dvt– sens = 80%
![Page 17: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/17.jpg)
Venography
• Gold standard (sens 100%, spec 100%)
![Page 18: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/18.jpg)
CHR Protocol
![Page 19: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/19.jpg)
Pulmonary Thromboembolism
![Page 20: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/20.jpg)
PE - diagnosis (V/Q scan)
• high probability V/Q scan (2 defects)
![Page 21: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/21.jpg)
PE - diagnosis (spiral CT scan)
![Page 22: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/22.jpg)
PE - diagnosis
Venography
- gold standard
- (100% / 100%)
![Page 23: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/23.jpg)
CHR Protocol
![Page 24: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/24.jpg)
![Page 25: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/25.jpg)
Overview of Prevention / Treatment
DVT PE
Prevent DVT
Patient at Risk
Death
Treat PE =Prevent
More PE
Treat DVT =Prevent PE
Treat PE
![Page 26: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/26.jpg)
Overview of Prevention / Treatment
Prevent DVT
Patient at Risk
![Page 27: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/27.jpg)
Risk of VTED among Non-prophylaxed Inpatients
![Page 28: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/28.jpg)
VTED Prevention in Medical Pts
• Medical in-patients– heart failure, severe resp disease, bedridden,
cancer, prev VTE, sepsis, acute neurologic disease, or inflammatory bowel disease
• recommend LDUH (1A) or LMWH (1A)
• if heparin contraindication, use mechanical prophylaxis with GCS or IPC (1C+)
![Page 29: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/29.jpg)
Heparins
• Dalteparin (Fragmin)– primarily used for prevention– 2,500 to 5,000 units sq od
• Tinzaparin (Innohep)– primarily used for DVT / PE therapy– 175 anti-Xa units / kg sq od
• Enoxaparin (Lovenox)– primarily used for acute coronary syndromes
![Page 30: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/30.jpg)
How LMWHs Differ - Molecular Weight Distribution
UFHTinzaparin
Enoxaparin
Molecular Weight (KDa)
2 3 4.5
6.5 15 30
![Page 31: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/31.jpg)
LMWH: Doses• Treatment: DVT or PE
– Tinzaparin 175 u/kg sc OD– Dalteparin 200 u/kg sc OD or 100 u/kg sc BID– Enoxaparin 1.5 mg/kg sc OD or 1 mg/kg sc BID
• Prophylaxis– Dalteparin 5000 u sc OD (2500 day of Orthopedic
surgery)– Enoxaparin 30 mg sc BID or 40 mg sc OD– Tinzaparin weight based or 4500 u sc OD
![Page 32: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/32.jpg)
What of those pre-filled syringes
• “Pre-filled syringes” are not useful as they do not allow me to exactly dose the patient
• Dose adjustment is likely unneeded as these drugs have a wide therapeutic window
– e.g. if the predicted dose is 12764 U I would feel very comfortable treating with 14000 unit pre-filled syringe
• What if my assurances are not enough ?
– Heparin is stable for some days if drawn up into a syringe by clinic staff and given to the patient
![Page 33: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/33.jpg)
Warfarin
• Inhibits the formation of Vitamin K dependent clotting factors 2, 7, 9, 10
• Inhibits formation of Protein C and S
• Overall, defective clotting proteins are formed
• Effect depends on depletion of previously made normal clotting proteins (2, 7, 9, 10)
• Not safe in pregnancy
![Page 34: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/34.jpg)
THR, TKR, Hip#, No Prophylaxis
Prox DVT% PE% Fatal PE%
THR 23-36 0.7-30 0.1-0.4
TKR 9-20 9-20 0.2-0.7
Hip# 17-36 4-24 3.6-12.9
![Page 35: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/35.jpg)
Recommendations: THR, TKR, Hip#
• LMWH started– 12 hr pre-op or (epidural hematoma risk)– 12-24 hr post-op or– 4-6 hr post-op at 1/2 dose
or• Warfarin started
– immediately pre-op– post-op
• Extended (post-discharge) may be acceptable
![Page 36: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/36.jpg)
Other Surgical Settings
• Consult CHEST supplement
![Page 37: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/37.jpg)
Take-Home-PointsDiagnosis of DVT and PE
• Prevention is standard of care.
• Guidelines are explicit.– medical– surgical
![Page 38: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/38.jpg)
Overview of Prevention / Treatment
DVT PE
Prevent DVT
Patient at Risk
Death
Treat PE =Prevent
More PE
Treat DVT =Prevent PE
Treat PE
![Page 39: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/39.jpg)
Overview of Prevention / Treatment
DVT PE
Treat PE =Prevent
More PE
Treat DVT =Prevent PE
![Page 40: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/40.jpg)
Why Intervene?
• Risk of PE among untreated DVT ~ 15-25%
• Risk of death among PE ~ 20-30%
• Risk of death among untreated DVT ~5%
• Risk of death for treated PE ~ 1.5%/yr
• Risk of death for treated DVT ~ 0.4%/yr
• Risk of major bleed treated PE/DVT ~1.0%/yr
![Page 41: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/41.jpg)
Suspected DVT
• If high clinical suspicion of DVT, treat with anticoagulants while awaiting the outcome of diagnostic tests (1C+).
![Page 42: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/42.jpg)
Confirmed DVT/PE• Clinical assessment risk / benefit of intervetion.• Draw baseline CBC, PTT, and INR and start:
Low Molecular Weight Heparinor
Adjusted Dose Unfractionated Heparin IVor
Adjusted Dose Unfractionated Heparin SQ
Any one of the three are acceptableLow Molecular Wt Heparin is preferred
(dosing, slightly better efficacy and safety)
![Page 43: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/43.jpg)
Duration of Heparin for acute DVT/PE
• Most Adults– minimum 5 days AND– until INR therapeutic for two consecutive days
• Active Cancer– minimum 3 – 6 months before converting to
‘indefinite’ warfarin
• Pregnant– therapeutic heparin until delivery– warfarin 4-6 weeks post-partum
![Page 44: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/44.jpg)
Duration of Warfarin for DVT/PE
• Warfarin (if not pregnant)– start concurrently with heparin– target INR 2.0 - 3.0
• Duration of warfarin– time reversible risk factors: > 3 months*– first idiopathic DVT/PE: > 6 months– recurrent DVT/PE: > 12 months– continuing risk factor > 12 months
• cancer and thrombophilias
*local tendency to tx PE x 6 months
![Page 45: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/45.jpg)
Thrombolysis for DVT?
![Page 46: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/46.jpg)
Thrombolysis for DVT?
![Page 47: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/47.jpg)
Thrombolysis for DVT?
![Page 48: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/48.jpg)
Therapy: Do we need to anticoagulate patients with acute VTE ?
Barrit and Jordan, Lancet 1960:1:1309
• Randomized trial of no-therapy vs subcutaneous heparin for patients with suspected acute PE
• Established the precedent for randomized trials in this area
Untreated
Treated
DeathsNon-fatal
recurrences
5 5
0 0
![Page 49: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/49.jpg)
Is this enough ?
![Page 50: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/50.jpg)
Do you need a fast acting a/c up front ?Brandjes et al. NEJM 1992:327;1485
– Patients with objectively proven acute lower-limb DVT– Randomized trial of IV standard heparin + oral
anticoagulants or oral anticoagulants alone
OAC alone
Heparin + OAC
Symptomaticrecurrences
Asymptomaticrecurrences
12 / 60 39.6 %
4 / 60 8.2 %
![Page 51: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/51.jpg)
Calf (below knee) DVT
• Below knee DVT extend proximally in 20% of patients treated with IV heparin for several days
• Recommend: treatment of below knee DVT is SAME AS proximal DVT
![Page 52: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/52.jpg)
Arm DVT
• Many recommendations– anticoagulation– thrombolysis– surgical extraction– catheter embolectomy
Latter three interventions science not persuasive
JPS I treat these similar to leg DVT
![Page 53: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/53.jpg)
Take-Home-PointsTreatment of DVT and PE
• Heparin– low molecular weight is preferred– duration is longer among cancer patients
• Warfarin– duration varies by clinical setting– implicit message that longer is better
![Page 54: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/54.jpg)
Overview of Prevention / Treatment
DVT PE
Prevent DVT
Patient at Risk
Death
Treat PE =Prevent
More PE
Treat DVT =Prevent PE
Treat PE
![Page 55: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/55.jpg)
Overview of Prevention / Treatment
PE Death
Treat PE
![Page 56: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/56.jpg)
Massive PE
• Thrombolytic Therapy– highly individualized– ICU admission
– reserved for echocardiographic right heart failure
![Page 57: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/57.jpg)
Thrombolysis for sub-massive PE
n = 238
Endpoint = escalation of therapy or death. NEJM 2002;347;1143
![Page 58: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/58.jpg)
Thrombolysis for sub-massive PE
![Page 59: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/59.jpg)
Post-Thrombotic Syndrome
• Variously defined– pain and swelling post-DVT– 20 – 50%
![Page 60: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/60.jpg)
Post-Phlebetic Syndrome• elastic compression stocking (30-40) during
2 years after an episode of DVT (1A)
• intermittent pneumatic compression for severe edema (2B)
• elastic compression stockings for mild edema of the leg due to the PTS (2C).
--------------
• Rutosides for mild edema due to PTS (2B)
![Page 61: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/61.jpg)
What are rutosides?
• A substance produced from leaves & flowers of the plant Sophora japonica
![Page 62: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/62.jpg)
![Page 63: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/63.jpg)
What to expect?
• Potential for post-phlebitic syndrome
• PE chest pain may come and go
• Hemoptysis may occur
• Elevate legs when not ambulating
• Okay to walk
![Page 64: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/64.jpg)
What happens to the Thrombus?
![Page 65: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/65.jpg)
Summary
• ACCP Guidelines– accessible– address most situations
• Other Topics– role of Anti-coagulation Management Clinics– perioperative care– travel– intolerance to heparin
![Page 66: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/66.jpg)
Anticoagulation in Special Risk Populations
Mark Crowther, MD, MSc, FRCPC
Associate Professor, Medicine and Haematology Residency Training Program Director
Acting Vice President, Research and Head of Service, Haematology
St Joseph’s HealthcareHamilton, Ontario, Canada
![Page 67: Management of DVT (and a little bit of PE, too) Jeffrey P Schaefer MSc MD FRCPC May 24, 2006.](https://reader035.fdocuments.us/reader035/viewer/2022062718/56649e845503460f94b86b38/html5/thumbnails/67.jpg)
Thanks to Borys Sydoruk
LEO Pharma Inc.